计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 4 篇同行评审文献引用。
概述
Ruxolitinib (INCB018424)是第一个应用于临床的、有效的、选择性的JAK1/2抑制剂，IC50为3.3 nM/2.8 nM。作用于JAK1， JAK2与 作用于JAK3相比，选择性强130倍多。An inhibitor of JAK1, JAK2, and JAK3.
Information
Ruxolitinib (INCB018424) is the first potent, selective,JAK1/2inhibitor to enter the clinic withIC50of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib indu
In vitro
INCB018424 potently and selectively inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. INCB018424 markedly increases apoptosis in a dose dependent manner in Ba/F3 cells. INCB018424 (64 nM) results in a doubling of cells with depolarized mitochondria in Ba/F3 cells. INCB018424 inhibits proliferating of erythroid progenitors from normal donors and polycythemia vera patients with IC50 of 407 nM and 223 nM, respectively. INCB018424 demonstrates remarkable potency against erythroid colony formation with IC50 of 67nM.
In vivo
INCB018424 (180 mg/kg, orally, twice a day) results in survive rate of greater than 90% by day 22 in a JAK2V617F-driven mouse model. INCB018424 (180 mg/kg, orally, twice a day) markedly reduces splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects in a JAK2V617F-driven mouse model. The primary end point is reached in 41.9% of patients in the Ruxolitinib group as compared with 0.7% in the placebo group in the double-blind trial of myelofibrosis. Ruxolitinib results in maintaining of reduction in spleen volume and improvement of 50% or more in the total symptom score. A total of 28% of the patients in the Ruxolitinib (15 mg twice daily) group has at least a 35% reduction in spleen volume at week 48 in patients with myelofibrosis, as compared with 0% in the group receiving the best available therapy. The mean palpable spleen length has decreased by 56% with Ruxolitinib but has increased by 4% with the best available therapy at week 48. Patients in the ruxolitinib group has an improvement in overall quality-of-life measures and a reduction in symptoms associated with myelofibrosis.
Cell Data
cell lines：NSCLC and Ba/F3 cells
Concentrations：3 μM
Incubation Time：48 hours
Powder Purity:≥98%
规格
英文别名
(3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
规格或纯度
10mM in DMSO
英文名称
Ruxolitinib (INCB018424)
生化机理
Ruxolitinib（INCB018424）是首个进入临床的强效、选择性 JAK1/2 抑制剂，在无细胞实验中的 IC50 为 3.3 nM/2.8 nM，对 JAK1/2 的选择性大于 JAK3 的 130 倍。Ruxolitinib 通过毒性有丝分裂杀死肿瘤细胞。Ruxolitinib可诱导自噬并促进细胞凋亡。
储存条件
-80℃储存
运输条件
特低温运输
名称和识别符
EC号
107-728-9
分子类型
小分子
Isomeric SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
PubChem CID
分子量
306.37
技术文档
高级数据
关联靶点（人）
TYK2
Tclin
非受体酪氨酸蛋白激酶 TYK2(Non-receptor tyrosine-protein kinase TYK2)
(0 活性数据)
HDAC6
Tclin
组蛋白去乙酰化酶6(Histone deacetylase 6)
(0 活性数据)
JAK3
Tclin
酪氨酸蛋白激酶JAK3(Tyrosine-protein kinase JAK3)
(0 活性数据)
JAK1
Tclin
酪氨酸蛋白激酶JAK1(Tyrosine-protein kinase JAK1)
(0 活性数据)
Tchem
未表征蛋白 FLJ45252(Uncharacterized protein FLJ45252)
(0 活性数据)
JAK2
Tclin
酪氨酸蛋白激酶JAK2(Tyrosine-protein kinase JAK2)
(0 活性数据)
化学和物理性质
溶解性
Solubility (25°C) In vitro DMSO: 45 mg/mL (201.54 mM); Ethanol: 45 mg/mL (201.54 mM); Water: Insoluble;
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 L2230025 |
分析证书 | R409244 |
技术文档和文章
JAK/STAT抑制剂
目录： 技术文章
JAK/STAT 抑制剂
目录： 技术文章
Small-Molecule Inhibitors: A Practical Guide for Research Selection — A Minimal Evidence Chain and Scenario-Based Validation Framework (Including a Selection Matrix, Case Cards, and Product Tables 1–4)
目录： 技术文章
Interleukin-29 (IL-29/IFN-λ1): Molecular Features, Signaling Networks, and a Systematic Framework for Research Applications
目录： 技术文章
此产品的引用文献
溶液计算器
常见问题
本产品应如何储存？
请于?80 °C条件下保存。需超低温保存以维持规定的有效期。
本产品如何运输？
本产品采用干冰配冷袋冷冻运输。收货后请立即拆包，并按上述储存条件保存；处理干冰时请戴隔热手套并保持通风。
本产品的 CAS 号、分子式和分子量是多少？
本产品的 CAS 号为 941678-49-5，分子式为 C17H18N6，分子量为 306.37 g/mol。
如何获取批次专用COA？
每个订单都会随附分析证书（COA），您也可以从账户订单历史中下载。如需订购前的COA，请联系您的客户代表，或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）